包装 | 价格(元) |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Preparation Method | The reaction was run in 8 complete rows (half plate) with or without a known inhibitor. S-adenosylhomocysteine was used as an inhibitor for METTL3-14. |
Reaction Conditions | 0-100?M S-adenosylhomocysteine |
Applications | S-adenosylhomocysteine showed strong inhibitory effects on METTL3-14 activity with an IC50 value of 0.9±0.1?M. |
Cell lines | WY2 and WY35(cys4? strains) |
Preparation Method | Saturated 2-day-old cultures of the WY2 and WY35 were diluted to an OD600 of approximately 0.05. S-adenosylhomocysteine was added at concentration at 25, 50, 100, 600?M. Growth was monitored by observing OD600 at specific time points during the course of 24h |
Reaction Conditions | 25, 50, 100, 600?M S-adenosylhomocysteine, 24h |
Applications | As little as 25?M S-adenosylhomocysteine showed measurable growth inhibition with the doubling time increasing about 15% from 222 to 256min. Exposure to 600?M S-adenosylhomocysteine increased the doubling time 206%, from 222 to 680min. |
Animal models | zebrafishes (F0) carrying the ahcyl1-KO allele |
Preparation Method | The identified chimeras were raised and crossed to wild-type zebrafish. The fertilized eggs were collected and injected with 0 or 5mM S-adenosylhomocysteine and RFP-LC3 mRNA at one-cell stage. For the injection of 5mM S-adenosylhomocysteine, the final concentration of injected S-adenosylhomocysteine was about 5?M. 26h after fertilization, the embryos were fixed by 8% paraformaldehyde with DAPI overnight. |
Dosage form | 0 or 5mM S-adenosylhomocysteine, the final concentration of injected S-adenosylhomocysteine was about 5?M, embryo injection, 26h |
Applications | Less LC3 puncta was observed when injected with S-adenosylhomocysteine. When one allele of ahcyl1 was knocked out, a mild increase of LC3 puncta was observed and the decrease of LC3 puncta by S-adenosylhomocysteine was significantly weakened. These results demonstrated that AHCYL1 senses the increased S-adenosylhomocysteine to inhibit autophagy in zebrafish. |
产品描述 | S-adenosylhomocysteine (SAH), an amino acid derivative, is a key intermediate metabolite in methionine metabolism[1]. It is an intermediate in the synthesis of cysteine and adenosine[2]. S-adenosylhomocysteine inhibited METTL3-14 activity with an IC50 value of 0.9 ± 0.1 µM[3]. S-adenosylhomocysteine(25 µM) inhibited the growth of CBS deficient yeast, but had no effect on wild-type yeast. Growth inhibition by S-adenosylhomocysteine in CBS deficient yeast can be totally reversed by addition of SAM to the media[4]. High S-adenosylhomocysteine levels inhibited NFκB-mediated gene expression and sensitized primary hepatocytes and HepG2 cells to the cytotoxic effects of TNF[5]. Increased adipose S-adenosylhomocysteine levels generate methylation defects that promote lipolysis. Alcohol-induced increases in hepatocellular S-adenosylhomocysteine and the resultant lowering of SAM/SAH ratio lead to the pathogenesis and progression of ALD[6]. S-adenosylhomocysteine enhances the interaction between AHCYL1 and PIK3C3. When cells are in the presence of S-adenosylhomocysteine, the enhanced interaction suppresses the production of PtdIns3P, which blocks the autophagy initiation. When in the absence of S-adenosylhomocysteine, the decreased interaction releases PIK3C3 to produce PtdIns3P, eventually promotes autophagy[1]. CKD was associated with a low SAM level and SAM/SAH ratio in urine. The use of the SAM level or the SAM/SAH ratio in urine could be considered as a promising, noninvasive indicator of renal dysfunction[7]. References: |